Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1994 1
1995 2
1996 2
1997 1
1998 1
2000 1
2002 1
2004 1
2007 3
2008 2
2009 1
2010 2
2011 5
2012 1
2014 1
2016 2
2018 2
2019 3
2020 7
2021 5
2022 3
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Page 1
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts.
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Mannent LP, Patel N, Staudinger HW, Yancopoulos GD, Mortensen ER, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Robinson LB, Abdulai RM; BOREAS Investigators. Bhatt SP, et al. N Engl J Med. 2023 Jul 20;389(3):205-214. doi: 10.1056/NEJMoa2303951. Epub 2023 May 21. N Engl J Med. 2023. PMID: 37272521 Clinical Trial.
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD, Haworth CS, Metersky ML, Loebinger MR, Blasi F, Sibila O, O'Donnell AE, Sullivan EJ, Mange KC, Fernandez C, Zou J, Daley CL; WILLOW Investigators. Chalmers JD, et al. N Engl J Med. 2020 Nov 26;383(22):2127-2137. doi: 10.1056/NEJMoa2021713. Epub 2020 Sep 7. N Engl J Med. 2020. PMID: 32897034 Clinical Trial.
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.
Di Pasquale MF, Sotgiu G, Gramegna A, Radovanovic D, Terraneo S, Reyes LF, Rupp J, González Del Castillo J, Blasi F, Aliberti S, Restrepo MI; GLIMP Investigators. Di Pasquale MF, et al. Clin Infect Dis. 2019 Apr 24;68(9):1482-1493. doi: 10.1093/cid/ciy723. Clin Infect Dis. 2019. PMID: 31222287 Free PMC article.
Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia.
Marin-Corral J, Pascual-Guardia S, Amati F, Aliberti S, Masclans JR, Soni N, Rodriguez A, Sibila O, Sanz F, Sotgiu G, Anzueto A, Dimakou K, Petrino R, van de Garde E, Restrepo MI; GLIMP investigators. Marin-Corral J, et al. Chest. 2021 Jan;159(1):58-72. doi: 10.1016/j.chest.2020.06.079. Epub 2020 Jul 17. Chest. 2021. PMID: 32687909 Free article.
Tracheobronchopathia osteochondroplastica.
Meyer CN, Døssing M, Broholm H. Meyer CN, et al. Respir Med. 1997 Sep;91(8):499-502. doi: 10.1016/s0954-6111(97)90117-7. Respir Med. 1997. PMID: 9338055 Free article. Review.
Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia.
Pascual-Guardia S, Amati F, Marin-Corral J, Aliberti S, Gea J, Soni NJ, Rodriguez A, Sibila O, Sanz F, Sotgiu G, Marcos PJ, Uranga A, Milenkovic B, Meyer CN, Kolditz M, Anzueto AR, Restrepo MI; GLIMP investigators. Pascual-Guardia S, et al. Among authors: meyer cn. Arch Bronconeumol. 2023 Feb;59(2):90-100. doi: 10.1016/j.arbres.2022.09.005. Epub 2022 Sep 22. Arch Bronconeumol. 2023. PMID: 36376121 English, Spanish.
Trichinella infection and clinical disease.
Clausen MR, Meyer CN, Krantz T, Moser C, Gomme G, Kayser L, Albrectsen J, Kapel CM, Bygbjerg IC. Clausen MR, et al. Among authors: meyer cn. QJM. 1996 Aug;89(8):631-6. doi: 10.1093/qjmed/89.8.631. QJM. 1996. PMID: 8935484 Review.
Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone.
Leding C, Bodilsen J, Brieghel C, Harboe ZB, Helleberg M, Holm C, Israelsen SB, Jensen J, Jensen TØ, Johansen IS, Johnsen S, Kirk O, Lindegaard B, Meyer CN, Mohey R, Pedersen L, Nielsen H, Nielsen SL, Omland LH, Podlekareva D, Ravn P, Starling J, Storgaard M, Søborg C, Søgaard OS, Tranborg T, Wiese L, Worm SHW, Christensen HR, Benfield T. Leding C, et al. Among authors: meyer cn. Infect Dis (Lond). 2023 May;55(5):351-360. doi: 10.1080/23744235.2023.2187081. Epub 2023 Mar 11. Infect Dis (Lond). 2023. PMID: 36905638
47 results